期刊
CURRENT OPINION IN ONCOLOGY
卷 22, 期 6, 页码 552-558出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CCO.0b013e32833de186
关键词
blood biomarkers; breast cancer; circulating tumor cells; prediction; prognosis
类别
资金
- La Fondation Fournier Majoie pour l' Innovation
- Fonds de la Recherche Scientifique - FNRS
- Medic Foundation
Purpose of review To critically review the latest findings concerning the role of circulating tumor cells (CTCs) and other blood biomarkers in breast cancer. Recent findings CTCs are epithelial tumor cells detected in the peripheral blood of patients with solid tumors using mainly cytometric/antibody-based and molecular approaches. Most technologies for CTC detection, including the FDA-approved CellSearch, are only detecting epithelial cell adhesion molecule (EpCAM)-positive CTCs and may miss clinically relevant subpopulations of CTCs. The value of CTC detection by CellSearch in metastatic breast cancer (MBC) may depend on the clinical setting and regimen used. In a retrospective analysis of 516 patients with MBC, CTC detection did not predict clinical outcome in chemo-naive women with HER2-positive MBC treated with anti-HER2 therapy, but had prognostic value in other breast cancer subtypes. Similarly, changes in CTCs during treatment did not predict outcome in 67 women treated with first-line bevacizumab/chemotherapy. CTC detection by CellSearch before or after adjuvant chemotherapy was associated with worse disease-free survival in 1489 patients with early breast cancer. Circulating nucleic acids, microRNAs and genomic rearrangements have been suggested as promising blood biomarkers. Summary Currently, there is no role for CTCs in clinical practice. The clinical utility of CTCs and other blood biomarkers should be prospectively tested.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据